News
REGN ▼ -1.8% - Regeneron Pharmaceuticals, Inc.
REGN ▼ -1.8% - Regeneron Pharmaceuticals, Inc.
$REGN - Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
25-OCT-2026 05:15 AM ET
Share this post
More filings for $REGN
REGN ▲ +2.2% - Regeneron Pharmaceuticals, Inc.Oct 12, 2026REGN ▼ -0.1% - Regeneron Pharmaceuticals, Inc.Oct 6, 2026REGN ▼ -3.3% - Regeneron Pharmaceuticals, Inc.Oct 1, 2026REGN ▼ -3.2% - Regeneron Pharmaceuticals, Inc.Oct 1, 2026REGN ▲ +1.1% - Regeneron Pharmaceuticals, Inc.Oct 1, 2026REGN ▼ -0.7% - Regeneron Pharmaceuticals, Inc.Sep 24, 2026
View full $REGN filing history →💬 Comments
Loading comments…
Leave a comment